vs
Side-by-side financial comparison of Hologic (HOLX) and ON Semiconductor (ON). Click either name above to swap in a different company.
ON Semiconductor is the larger business by last-quarter revenue ($1.6B vs $1.0B, roughly 1.5× Hologic). Hologic runs the higher net margin — 17.1% vs 16.4%, a 0.7% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -10.0%). ON Semiconductor produced more free cash flow last quarter ($372.4M vs $215.2M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -12.3%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Fairchild Semiconductor International, Inc. was an American semiconductor company based in San Jose, California. It was founded in 1957 as a division of Fairchild Camera and Instrument by the "traitorous eight" who defected from Shockley Semiconductor Laboratory. It became a pioneer in the manufacturing of transistors and of integrated circuits. Schlumberger bought the firm in 1979 and sold it to National Semiconductor in 1987; Fairchild was spun off as an independent company again in 1997. I...
HOLX vs ON — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.6B |
| Net Profit | $179.1M | $255.0M |
| Gross Margin | 56.0% | 37.9% |
| Operating Margin | 22.6% | 17.0% |
| Net Margin | 17.1% | 16.4% |
| Revenue YoY | 2.5% | -10.0% |
| Net Profit YoY | -10.9% | -32.9% |
| EPS (diluted) | $0.79 | $0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.6B | ||
| Q3 25 | $1.0B | $1.5B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | $1.7B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.7B | ||
| Q1 24 | $1.0B | $1.9B |
| Q4 25 | $179.1M | $255.0M | ||
| Q3 25 | $187.2M | $170.3M | ||
| Q2 25 | $194.9M | $-486.1M | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $201.0M | $379.9M | ||
| Q3 24 | $178.6M | $401.7M | ||
| Q2 24 | $194.5M | $338.2M | ||
| Q1 24 | $169.9M | $453.0M |
| Q4 25 | 56.0% | 37.9% | ||
| Q3 25 | 55.6% | 37.6% | ||
| Q2 25 | 56.3% | 20.3% | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | 45.2% | ||
| Q3 24 | 56.4% | 45.4% | ||
| Q2 24 | 55.4% | 45.2% | ||
| Q1 24 | 53.3% | 45.8% |
| Q4 25 | 22.6% | 17.0% | ||
| Q3 25 | 22.6% | 13.2% | ||
| Q2 25 | 24.9% | -39.7% | ||
| Q1 25 | -0.7% | — | ||
| Q4 24 | 22.5% | 23.7% | ||
| Q3 24 | 23.3% | 25.3% | ||
| Q2 24 | 24.1% | 22.4% | ||
| Q1 24 | 20.7% | 28.2% |
| Q4 25 | 17.1% | 16.4% | ||
| Q3 25 | 17.8% | 11.6% | ||
| Q2 25 | 19.0% | -33.6% | ||
| Q1 25 | -1.7% | — | ||
| Q4 24 | 19.7% | 22.1% | ||
| Q3 24 | 18.1% | 22.8% | ||
| Q2 24 | 19.2% | 19.5% | ||
| Q1 24 | 16.7% | 24.3% |
| Q4 25 | $0.79 | $0.63 | ||
| Q3 25 | $0.84 | $0.41 | ||
| Q2 25 | $0.86 | $-1.15 | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $0.87 | $0.88 | ||
| Q3 24 | $0.75 | $0.93 | ||
| Q2 24 | $0.82 | $0.78 | ||
| Q1 24 | $0.72 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $2.9B |
| Total DebtLower is stronger | $2.5B | $3.4B |
| Stockholders' EquityBook value | $5.2B | $7.9B |
| Total Assets | $9.2B | $13.0B |
| Debt / EquityLower = less leverage | 0.48× | 0.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $2.9B | ||
| Q3 25 | $2.2B | $2.8B | ||
| Q2 25 | $1.9B | $3.0B | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | $3.0B | ||
| Q3 24 | $2.3B | $2.8B | ||
| Q2 24 | $2.4B | $2.7B | ||
| Q1 24 | $2.2B | $2.6B |
| Q4 25 | $2.5B | $3.4B | ||
| Q3 25 | $2.5B | $3.4B | ||
| Q2 25 | $2.5B | $3.4B | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $3.4B | ||
| Q3 24 | $2.5B | $3.4B | ||
| Q2 24 | $2.5B | $3.4B | ||
| Q1 24 | $2.6B | $3.4B |
| Q4 25 | $5.2B | $7.9B | ||
| Q3 25 | $5.0B | $7.9B | ||
| Q2 25 | $4.8B | $8.0B | ||
| Q1 25 | $4.6B | — | ||
| Q4 24 | $4.8B | $8.8B | ||
| Q3 24 | $5.1B | $8.6B | ||
| Q2 24 | $5.0B | $8.3B | ||
| Q1 24 | $4.8B | $8.1B |
| Q4 25 | $9.2B | $13.0B | ||
| Q3 25 | $9.0B | $13.1B | ||
| Q2 25 | $8.8B | $13.3B | ||
| Q1 25 | $8.5B | — | ||
| Q4 24 | $8.7B | $14.1B | ||
| Q3 24 | $9.2B | $13.9B | ||
| Q2 24 | $8.9B | $13.7B | ||
| Q1 24 | $8.7B | $13.5B |
| Q4 25 | 0.48× | 0.43× | ||
| Q3 25 | 0.50× | 0.43× | ||
| Q2 25 | 0.52× | 0.42× | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.38× | ||
| Q3 24 | 0.49× | 0.39× | ||
| Q2 24 | 0.51× | 0.41× | ||
| Q1 24 | 0.53× | 0.42× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $418.7M |
| Free Cash FlowOCF − Capex | $215.2M | $372.4M |
| FCF MarginFCF / Revenue | 20.5% | 24.0% |
| Capex IntensityCapex / Revenue | 1.4% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.64× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $418.7M | ||
| Q3 25 | $355.1M | $184.3M | ||
| Q2 25 | $343.3M | $602.3M | ||
| Q1 25 | $169.4M | — | ||
| Q4 24 | $189.3M | $579.7M | ||
| Q3 24 | $367.0M | $465.8M | ||
| Q2 24 | $405.8M | $362.2M | ||
| Q1 24 | $292.4M | $498.7M |
| Q4 25 | $215.2M | $372.4M | ||
| Q3 25 | $341.4M | $106.1M | ||
| Q2 25 | $330.5M | $454.7M | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | $434.8M | ||
| Q3 24 | $350.6M | $293.6M | ||
| Q2 24 | $385.3M | $207.7M | ||
| Q1 24 | $279.6M | $276.3M |
| Q4 25 | 20.5% | 24.0% | ||
| Q3 25 | 32.5% | 7.2% | ||
| Q2 25 | 32.3% | 31.5% | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | 25.2% | ||
| Q3 24 | 35.5% | 16.7% | ||
| Q2 24 | 38.1% | 12.0% | ||
| Q1 24 | 27.5% | 14.8% |
| Q4 25 | 1.4% | 3.0% | ||
| Q3 25 | 1.3% | 5.3% | ||
| Q2 25 | 1.3% | 10.2% | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | 8.4% | ||
| Q3 24 | 1.7% | 9.8% | ||
| Q2 24 | 2.0% | 8.9% | ||
| Q1 24 | 1.3% | 11.9% |
| Q4 25 | 1.28× | 1.64× | ||
| Q3 25 | 1.90× | 1.08× | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | 1.53× | ||
| Q3 24 | 2.05× | 1.16× | ||
| Q2 24 | 2.09× | 1.07× | ||
| Q1 24 | 1.72× | 1.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
ON
| Industrial Segment | $426.3M | 27% |
| Other End Markets Segment | $337.3M | 22% |
| Intelligent Sensing Segments | $284.0M | 18% |
| Direct Customers | $282.4M | 18% |
| Intelligent Sensing Group | $230.0M | 15% |
